Compare DDD & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | SLN |
|---|---|---|
| Founded | 1986 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.8M | 318.4M |
| IPO Year | N/A | N/A |
| Metric | DDD | SLN |
|---|---|---|
| Price | $1.78 | $6.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.75 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 3.4M | 309.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $391,651,000.00 | $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $1.32 | $1.97 |
| 52 Week High | $5.00 | $8.08 |
| Indicator | DDD | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 44.28 |
| Support Level | $1.82 | $6.11 |
| Resistance Level | $1.93 | $6.59 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 14.34 | 12.87 |
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.